<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="activation, heme formation, and the immune response is responsible for" exact="infection" post="diffusion, endothelial dysfunction, vasoconstriction, oxidative damage and releasing of"/>
 <result pre="and 14 days. The clinical severity ranges widely from asymptomatic" exact="infection" post="to fatal disease. The involvement of the upper respiratory"/>
 <result pre="and green the main activation pathways both of the virus" exact="infection" post="modality, of the pathogenetic mechanisms of the damage, and"/>
 <result pre="in people with hypertension, diabetes, and vascular disease. 2.1 Pulmonary" exact="infection" post="and pathological findings Mainly, the SARS-CoV-2 is responsible for"/>
 <result pre="damage by COVID-19. There are autopsy data relating to the" exact="infection" post="produced by SARS CoV in 2003 and by MERS-CoV"/>
 <result pre="However, these data are affected by the difficulty of autopsy" exact="diagnosis" post="made in a particular background. For example, an autopsy"/>
 <result pre="death in patients with previous cardiovascular disease. Because the pandemic" exact="infection" post="broke out in a very short time, there are"/>
 <result pre="These aspects do not allow to make a correct differential" exact="diagnosis" post="because they lack a conspicuous consistency of the data"/>
 <result pre="time in hospitalized patients with severe COVID-19 and non-survivors; DIC" exact="diagnosis" post="was performed according to clinical and laboratory criteria [[42],"/>
 <result pre="Clinical studies in cancer patients report a higher risk of" exact="infection" post="than in a non-cancerous population (median age 66 years)"/>
 <result pre="effects are already known to have been re-evaluated in the" exact="treatment" post="[[49], [50], [51], [52], [53], [54], [55], [56], [57],"/>
 <result pre="[58], [59]]; has been used for years as components of" exact="treatment" post="for HIV [55,60] it may interfere with the dosage"/>
 <result pre="on RdRp has been used for years as components of" exact="treatment" post="for hepatitis C [55], has broad-spectrum activities against viruses"/>
 <result pre="[56]. Hydroxychloroquine (HCQ) was originally developed and used for the" exact="treatment" post="of malaria and it is increasingly used in the"/>
 <result pre="confusing. Contrary, some authors indicate overexpression of ACE2 in SARS-CoV-2" exact="infection" post="[86,87], which we could explain as a rebound effect"/>
 <result pre="anti-RAAS or ACE inhibitors have a higher risk of SARS-CoV-2" exact="infection" post="or that they have a higher cardiovascular risk. Furthermore,"/>
 <result pre="a higher cardiovascular risk. Furthermore, an up-regulation would favor greater" exact="treatment" post="efficacy and protection rather than risk. Some authors suggest"/>
 <result pre="authors suggest the protective role of ace inhibitors against SARS-CoV-2" exact="infection" post="as opposed to others. However, we still have doubts"/>
 <result pre="viruses into cells and statins are reported to block the" exact="infection" post="of many enveloped viruses by inhibiting the cholesterol pathway"/>
 <result pre="cholesterol pathway [89,90]. The use of statins in EBOLA virus" exact="infection" post="is described as a protective factor [91,92]. Besides, for"/>
 <result pre="Sci Res.4August 19 (3)201924725610.1080/20961790.2019.159535231489390 32MattioliA.V.Ballerini PuvianiM.NasiM.FarinettiA.COVID-19 pandemic: the effects of" exact="quarantine" post="on cardiovascular riskEur. J. Clin. Nutr.5202010.1038/s41430-020-0646-zMay 33FosterE.D.CavanaughJ.E.HaynesW.G.YangM.GerkeA.K.TangF.PolgreenP.M.Acute myocardial infarctions,"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of Lopinavir/Ritonavir for the treatment"/>
 <result pre="COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the" exact="treatment" post="of COVID-19 infected pneumonia monitored by quantitative RT-PCRJ. Korean"/>
 <result pre="(6)2020e7910.3346/jkms.2020.35.e7932056407 59ChuC.M.ChengV.C.HungI.F.WongM.M.ChanK.H.ChanK.S.KaoR.Y.PoonL.L.WongC.L.GuanY.PeirisJ.S.YuenK.Y.HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59March (3)200425225614985565 60SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic"/>
 <result pre="US cohort (LUMINA L)Ann. Rheum. Dis.6620071168117217389655 63WillisR.SeifA.M.Jr McGwinG.Martinez-MartinezL.A.GonzÃ¡lezE.B.DangN.PapalardoE.LiuJ.VilÃ¡L.M.ReveilleJ.D.AlarcÃ³nG.S.PierangeliS.S.Effect of hydroxychloroquine" exact="treatment" post="on pro-inflammatory cytokines and disease activity in SLE patients:"/>
 <result pre="Immunotoxicol.35June (3)201343444210.3109/08923973.2013.78007823635029 68GaoJ.TianZ.YangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci. Trends14March 16"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect."/>
 <result pre="Infect. Dis.9202010.1093/cid/ciaa237Mar pii: ciaa237 71GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
 <result pre="antimalarial drugsLancet Infect. Dis.7200754955817646028 74WozniackaA.CygankiewiczI.ChudzickM.The cardiac safety of chloroquine phosphate" exact="treatment" post="in patients with systemic lupus erythematosus: the influence on"/>
 <result pre="our experience in forensic thanatologyLeg Med (Tokyo).352018121710.1016/j.legalmed.2018.09.003November30232046 97RussoC.V.SaccÃ F.PaternosterM.BuonomoA.R.GentileI.ScottoR.Brescia MorraV.MansuetoG.Post-mortem" exact="diagnosis" post="of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple"/>
 <result pre="97RussoC.V.SaccÃ F.PaternosterM.BuonomoA.R.GentileI.ScottoR.Brescia MorraV.MansuetoG.Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab" exact="treatment" post="for multiple sclerosisMult. Scler.26January (1)202012312610.1177/135245851881311030882274 98de NigrisF.CacciatoreF.ManciniF.P.VitaleD.F.MansuetoG.Dâ€™ArmientoF.P.SchianoC.SoricelliA.NapoliC.Epigenetic Hallmarks of"/>
</results>
